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Brachydactyly (BD) refers to the shortening of the hands, feet or both. There are different types of BD; among them,
type E (BDE) is a rare type that can present as an isolated feature or as part of more complex syndromes, such as:
pseudohypoparathyroidism (PHP), hypertension with BD or Bilginturan BD (HTNB), BD with mental retardation
(BDMR) or BDE with short stature, PTHLH type. Each syndrome has characteristic patterns of skeletal involvement.
However, brachydactyly is not a constant feature and shows a high degree of phenotypic variability. In addition,
there are other syndromes that can be misdiagnosed as brachydactyly type E, some of which will also be discussed.
The objective of this review is to describe some of the syndromes in which BDE is present, focusing on clinical,
biochemical and genetic characteristics as features of differential diagnoses, with the aim of establishing an
algorithm for their differential diagnosis. As in our experience many of these patients are recruited at Endocrinology
and/or Pediatric Endocrinology Services due to their short stature, we have focused the algorithm in those steps
that could mainly help these professionals.Brachydactyly (BD) refers to a family of limb malfor-
mations characterized by shortening of the hands, feet or
both [1]. It was added to the international Nosology and
Classification of Genetic Skeletal Disorders in 2001, in the
group of genetically determined dysostoses [2,3]. Different
types of brachydactyly can be distinguished based on ana-
tomic grounds, the most commonly used classification be-
ing that provided by Bell [4] and modified by Temtamy &
McKusick [5]. Most types are rare, except for A3 (BDA3,
OMIM#112700) and D (BDD, OMIM#113200) that have
a prevalence of around 2% [1]. In this review, we focus on
brachydactyly type E (BDE, OMIM#113300), which is rare
and can be diagnosed as an isolated finding or as part of
several genetic syndromes [1,5,6].
BDE encompasses variable shortening of the metacar-
pals/metatarsals, frequently with involvement of the pha-
langes [5]. Hertzog [7] classified BDE into three distinct
varieties: type E1, with shortening of metacarpal IV, some-
times associated with shortening of metatarsal IV (possible
involvement of an isolated metatarsal); type E2, with
shortening of metacarpals IV and V (and metatarsals)* Correspondence: gnanclares@osakidetza.net
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reproduction in any medium, provided the orassociated with shortening of the distal phalanx of the
thumb; and type E3, with various combinations of short
metacarpals without phalangeal involvement [8]. However,
these patterns are not held to exactly in all syndromes; as
well as the distal phalanx of the thumb, others phalanges
are often shortened.
In this review, we describe some common syndromes in
which BDE is present, outlining their main clinical, bio-
chemical and genetic characteristics (Additional file 1:
Table S1), with the aim of establishing an algorithm for
the accurate diagnosis of BDE in association with other
features. Even if acrodysostosis and tricho-rinho-phalan-
geal syndrome cannot be considered as conditions with a
pure brachydactyly E, as they have peculiar radiological
features, sometimes they are misdiagnosed as syndromic
BDE, so we will try to define the specific characteristics
that distinguish them from all the other conditions.
One of these specific features is multihormonal resist-
ance, mainly to parathyroid hormone (PTH) and thyroid
hormone (TSH). We use this feature to classify the syn-
dromes into two groups depending on the presence of
multihormonal resistance as many of these patients are
recruited at Endocrinology and/or Pediatric EndocrinologyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of hormonal profile.
Isolated brachydactyly type E: HOXD13 type
(OMIM#113300)
While BDE is commonly reported as part of a syndrome,
it occasionally appears as an isolated entity [9-11]. Four
heterozygous mutations in the homeobox D13 gene
(HOXD13, 2q31.1), two missenses and two nonsenses,
have been identified as causative of isolated BDE [9-12]. In
two of these four cases, an overlap between BDE and BDD
(shortening of the distal phalanx of the thumb) was noted
in the patients [9]. Other hand malformations that have
been observed in combination with BDE are syndactyly of
digits III and IV, synpolydactyly of finger IV, and long dis-
tal phalanges [9]. In addition, 21 independent mutations
have been identified in HOXD13, most of them producing
synpolydactyly (SPD; OMIM#186000), or in rare cases
syndactyly, and other unspecified limb malformations [11].
Regarding BDE caused by mutations in HOXD13, the
pattern profile showed many variations between affected
patients: most of them had shortening of metacarpals III
and sometimes also IV and V (Figure 1A); and in the feet,
shortening of the metatarsals IV was frequently seen,
sometimes in combination with that of metatarsals I, III or
V and broadening of the hallux (Figure 1B). In addition,
little-finger distal phalanx hypoplasia/aplasia, lateral pha-
langeal duplication and/or clinodactyly of finger IV, and
syndactyly of fingers III/IV were frequently observed
[9,11,13]. Finally, in general, affected individuals had nor-
mal stature and no appreciable psychomotor developmen-
tal delay (Additional file 1: Table S2) [9,11,13,14].
Brachydactyly type E as part of syndromes
BDE with multihormonal resistance
Pseudohypoparathyroidism
Pseudohypoparathyroidism (PHP) refers to several distinct,
but related, disorders in which resistance to parathyroidFigure 1 Radiographs of hands (A) and feet (B) of a non adult individ
(courtesy of Dr. Aleksander Jamsheer). Shortening and widening of IV a
brachyphalangy, and mild clynodactyly of the distal phalanx of II and V, in
in right feet II, III, IV are shortened and in the left one, only III and IV. Notehormone (PTH) is the most prominent feature [15]. How-
ever, resistance to thyroid-stimulating hormone (TSH)
and several other pituitary hormones that mediate their
action through G-protein-coupled receptors is often
present as well. As a result of PTH resistance, patients
with PHP develop hypocalcaemia and hyperphospha-
taemia. Resistance seems to occur only in the proximal
renal tubule, while the action of PTH is unimpaired in
other target tissues, such as bone and the renal thick as-
cending limb [16-18].
BDE is present in 70-78% of individuals with PHP [19].
There are, however, great differences in hand shortening:
some patients display severe shortening of all hand bones,
whereas commonly in others metacarpals and distal pha-
langes are more impaired than other segments. In particu-
lar, Poznanski et al. reported that the distal phalanx of the
thumb and metacarpal IV were the most affected in 75%
and 65% of patients respectively [20]. On the other hand,
while de Sanctis et al. did not observe differences in preva-
lence of shortening, they reported that metacarpal V and
distal phalanges I and IV were the most severely affected
(85.7% < −2 SDS) (Figure 2) [19]. They also noted varia-
tions in the patterns of bone shortening between subjects
with the same mutation, within the same family as well as
among unrelated individuals [19]. Most publications on
PHP only mention shortening of metacarpals III, IV and V
or metatarsals, but it should be clarified that the shorten-
ing of these bones is usually more evident than shortening
of phalanges; the latter may also occur, but is more diffi-
cult to assess because of the wide range of variation within
the normal population [21].
PHP is associated with alterations in the GNAS locus,
which maps to the telomeric end of the long arm of
chromosome 20 (20q13.2-20q13.3) [22]. GNAS exempli-
fies a locus of high complexity [23]. One of its products is
the α-subunit of the stimulatory heterotrimeric G protein
(Gsα), a ubiquitous signalling protein that is essential for
numerous different cellular responses. Gsα expression isual with heterozygous mutation in HOXD13(OMIM#113300)
nd V metacarpals are more evident in right; I, IV and V distal
left hand. In the feet, note asymmetrical shortening of the metatarsals:
also, the clynodactyly of right hallux.
Figure 2 Hand of a patient with pseudohypoparathyroidism
type Ia (OMIM#103580). Note the shortening of first metacarpal
and proximal phalanx of the thumb and more severe shortening of
metacarpals IV and V (courtesy of Dr. Beatriz Garcia-Cuartero).
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lenced in a few types of tissue (renal tubule, thyroid gland,
hypophysis and gonads) [24-26] and this is important in
the development of phenotypes associated with GNAS
mutations. Maternal imprinting (and thus paternal expres-
sion) occurs on XLαs, the large form of Gsα, and two
non-coding RNA molecules, the A/B transcript and the
NESPas antisense transcript. On the other hand, paternal
imprinting is seen on NESP55, a chromogranin like neuro-
endocrine secretory protein [27].
Heterozygous inactivating mutations within Gsα-
encoding GNAS exons, leading to diminished activity, are
found in patients with PHP-Ia (OMIM#103580). These
patients have not only resistance to hormones but also the
Albright’s hereditary osteodystrophy (AHO) phenotype
(as an example, see Figure one at Miao et al. [28])
(Additional file 1: Table S3) [27]. This phenotype includes
BDE (Figure 2), small stature, obesity with a rounded face,
subcutaneous calcifications, and mental retardation [29].
Patients with AHO features but no evidence of hormone
resistance are said to have pseudopseudohypoparathy-
roidism (PPHP, OMIM#612463), and also carry heterozy-
gous inactivating Gsα mutations. Maternal inheritance of
such a mutation leads to PHP-Ia, AHO and hormoneresistance, while paternal inheritance of the same muta-
tion causes PPHP [27].
On the other hand, PHP-Ib (OMIM#603233) is another
form of PHP which can follow an autosomal dominant
(AD) trait (AD-PHP-Ib) or occur as a sporadic disorder.
These patients present with PTH and sometimes TSH re-
sistance, but resistance for other hormones is not found.
Apart from this, patients often lack AHO features and ex-
hibit normal Gsα activity in erythrocytes and fibroblasts.
Nevertheless, there have been some reports of patients
with mild AHO [30-33] and these individuals have dimin-
ished Gsa activity [34]. Generally, AD-PHP-Ib is caused by
specific deletions in the syntaxin 16 gene (STX16)
(STX16del4-6 or STX16del2-4); which are associated with
maternal inheritance and cause loss of methylation at
GNAS exon A/B or 1A. Other form of AD-PHP-Ib, due to
maternally inherited microdeletions of NESP55 identified
within GNAS, produces a loss of all maternal GNAS
methylation imprints [35,36].
Sporadic PHP-Ib cases also display GNAS imprinting
abnormalities that involve NESPas, XLαs and A/B. How-
ever, the genetic lesion, if any, underlying these epigen-
etic defects remains to be discovered and most of these
cases could represent true stochastic errors in early em-
bryonic maintenance of methylation [37-39]. Some of
these patients have been shown to be affected by pater-
nal uniparental isodisomy (pat20iUPD) involving part or
the whole long arm of chromosome 20, which includes
the GNAS locus [39-42]. A mild BDE and AHO pheno-
type has been reported in some studies [30,31,43]; in
most cases, only metacarpal IV and/or V shortening was
seen, although mild shortening of all metacarpals and
some distal phalanges has also been described [33].
Sanchez et al. found BDE in 60% of patients with PHP-Ib
in their study (no subjects presenting shortening of distal
phalanx I). In two patients, BDE was combined with
Madelung-like deformities (involvement of the distal ulna
and radius) [43]. On the other hand, Mantovani et al. did
not find any correlation between the severity of the AHO
phenotype and methylation defects, their patients’ pheno-
type ranging from mild to severe AHO [33].
Acrodysostosis with multihormonal resistance (ACRDYS1,
OMIM#101800)
Parathyroid hormone-related protein and G-proteins are
part of the same signalling pathway affecting cartilage
differentiation and growth in the metacarpals. This could
explain the similarity of PTHLH-related BDE, pseudo-
hypoparathyroidism and acrodysostosis.
Acrodysostosis is a rare skeletal dysplasia characterized
by severe generalized brachydactyly of hands (Figure 3)
and feet with a relatively long first thumb, dysostosis, short
stature and facial abnormalities: typically a round face with
maxillary and nasal hypoplasia; but sometimes also an
Figure 3 Hand of a patient with acrodysostosis and
multihormonal resistance (OMIM#101800). Severe and
generalized brachydactyly, through very short and broad tubular
bones, including ulna can be observed. Metacarpals II-V are
proximally pointed and cone-shaped proximal phalangeal epiphyses
are prematurely fused. The general appearance of the hand is bulky
and stocky (courtesy of Prof. Dr. Jesús Argente).
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canthal folds and hypertelorism (see Figure Three Pt.7, 8,
11 at Linglart et al. [44]). Advanced skeletal maturation,
spinal stenosis, obesity, mental deficiency, notably delayed
speech and impaired hearing are also frequently ob-
served (Additional file 1: Table S4) [44-51]. Although
Maroteaux & Malamut defined this pathology as a newFigure 4 Hands of a patient with Bilginturan BD or HTNB (OMIM%112
articular surfaces and cup deformity in the epiphysis of the proximal and m
but the proximal and middle phalanges of the III and IV digits are relatively
unpublished case).syndrome distinct from PHP/AHO in 1968 [47], these
two entities have been confused many times because
they share many features [44]. One of these is
multihormonal resistance to PTH or TSH [52], though
it is not always present as there are several forms of
acrodysostosis and the genes involved are different (see
below) [44]. In the case of acrodysostosis with multi-
hormonal resistance (ACRDYS1, OMIM#101800), the
gene responsible is cAMP-dependent protein kinase A
(PRKAR1A), which has been localized to 17q24.2 and is
involved in the signalling pathway downstream of
GNAS. This is the reason for resistance to PTH and
other hormones, as in PHP [44,48].
The characteristic feature in this syndrome is severe
BDE, characterized by shortening of metacarpals/meta-
tarsals and phalanges II-V, phalangeal epiphyses being
cone-shaped and prematurely fused, and affected bones
appearing bulky and stocky (Figure 4) [44,45,48], while
thumbs and halluces tend to be less affected [44,52,53]. In
addition, a decreased interpedicular distance has been rep-
orted in 75% of patients. These severe brachydactyly and
vertebral abnormalities have not been noted in PHP pa-
tients, so they could help us to differentiate between these
two syndromes [45,52]. Finally, another type of feature
that could aid the differential diagnosis is subcutaneous
ossification, as this is not seen in acrodysostosis [45,52].
BDE without multihormonal resistance
Short stature
Bilginturan BD or hypertension with brachydactyly
syndrome (HTNB, OMIM%112410) Bilginturan et al.
were the first to describe this syndrome in a large non-
consanguineous Turkish family [54]. Subsequently, other
authors have also studied this family and its new genera-
tions [55-66]. Affected members of the family had severe410). Metacarpals are short (specially II-V) with globular ends, irregular
edial phalanges. All the phalanges of the hands are also shortened,
normal (courtesy of Dr. Sylvia Bähring and Dr. Okan Toka,
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and unaffected family members) from childhood [54]
and a stroke by the age of 50 years if untreated [56]. Al-
most all the affected children have systolic blood pres-
sure values over the 99th percentile [66]. However, the
renin-angiotensin-aldosterone system (supine and upright)
and circulating catecholamines respond normally, patients
were not salt sensitive, their renal function was normal,
they had no retinopathy or cardiac enlargement and the in-
crease in radial wall thickness was minimal [55,56,59]. Af-
fected individuals also presented BDE, were on average
10 cm shorter and had lower mean birth weight than their
unaffected relatives, as well as having a stocky build and ra-
ther round face (see Figures two a & three a at Bilginturan
et al. [54]) (Additional file 1: Table S5) [54,56,66].
Brachydactyly among the affected Turkish family
members was heterogeneous. In most cases, shortening
of more than one metacarpal and metatarsal was present
[54], digits IV and V being most frequently affected but,
in some cases, shortening has been seen in all the meta-
carpals and metatarsals in this and other families
[56,57,66,67]. Further, the shortening is not always sym-
metrical. All the phalanges of the hand were shortened,
but the proximal and middle phalanges of the III and IV
digits were relatively normal. Phalanges revealed cone-
shaped epiphyses at proximal ends. All the phalanges of
the toes were shortened and some patients presented
symmetrical fusion between the middle and distal pha-
langes of toes IV and V, or only V (Figure 4). Addition-
ally, shortening of carpal bones in the axial direction
was also observed [54]. Bähring et al. compared the
brachydactyly pattern profile of a 5.5-year-old Japanese
patient, who carried a de novo (12) (p11.21p12.2) chro-
mosomal deletion [68], with a 6-year-old boy from the
Turkish family [57]. Both boys presented almost identi-
cal brachydactylies; type 16 cone-shaped epiphyses, par-
ticularly in the proximal interpahalangeal joints of
digits II and V, brachyphalangy of digits II-IV and
brachymetacarpalia of digits IV and V. The Japanese
patient presented brachymesophalangy and cone-
shaped epiphyses in digits II-V, and the Turkish boy
only in digits II and V [57]. Intellectual disability, sub-
cutaneous calcifications, obesity or differences in body
mass index have not been observed [55,57,66], except
in an isolated case reported by Derbent et al., where
the patient presented obesity and a defect in the left
renal artery [69]. It is important to highlight that
brachydactyly is not appreciable until around 6 years of
age and it aggravates significantly during early puberty
as a result of an impaired growth spurt at the pre-
pubertal stage. Given this, it is important to pay atten-
tion to the first signs of brachydactyly when an
elevated blood pressure is detected in children (systolic
blood pressure values >99th percentile) [66].Another clinical feature in the Turkish family was the
presence of aberrant posterior inferior cerebellar artery
(PICA) loops only in affected members. Naraghi et al.
[70] reported 100% loop cosegregation with hyperten-
sion and brachydactyly in a group of 27 members of the
Turkish family (15 affected and 12 unaffected). The
prevalence of the loops was not influenced by age or sex.
Further, a brief report described a case of a boy with the
same syndrome not only with the PICA abnormality but
also abnormal renal arteries [71]. Additional studies
found that affected individuals showed less active sym-
pathetic nerve traffic to muscle than unaffected family
members and also could not buffer blood pressure-
elevating effects of phenylephrine [60,65]. These findings
confirmed that baroreflex blood pressure buffering was
impaired in affected individuals [60,66]. The arterial
baroreflex is a critical cardiovascular reflex that provides
continuous buffering of acute fluctuations in arterial
blood pressure due, for example, to changes in posture,
exercise, and emotion [72]. PICA loops can produce
neurovascular compression of the ventrolateral medulla
at the root entry zone of cranial nerves IX and X [63,70],
which are very important in the baroreflex mechanism.
Arterial baroreceptors are mechanoreceptors: those lo-
cated in the carotid sinuses are innervated by cranial
nerve IX and those in the aortic arch by cranial nerve X.
When arterial pressure increases, these nerves send an
input to the nucleus of the solitary tract and barosensitive
neurons from here initiate a sympatho-inhibitory path-
way to reduce arterial blood pressure [72].
The molecular basis for this syndrome is unknown,
but several researchers have found evidence of linkage
to chromosome 12p, specifically to 12p11.21-12p.12.2
[55,56,73,74]. Surprisingly, in a genome-wide linkage ana-
lysis, chromosome 12p was also implicated in Chinese pa-
tients with primary hypertension (not brachydactyly) [75].
Bahring et al. identified a complex rearrangement involv-
ing a deletion, reinsertion and inversion of the 12p12.2-
p12.1 region [64]. This region is, however, relatively gene
poor, only further characterized expressed sequence tags
(EST) being identified in the vicinity [64]. These authors
also proposed Kir6.1, SUR2, LSOX5 and PDE3A, which
are within the studied segment, as candidate genes. Al-
though, no alterations were found in these genes, a higher
mRNA expression of PDE3A was detected in older af-
fected family members (while the younger subjects af-
fected showed expression values in the same range as
those unaffected). On this basis, they suggested that the
higher vascular expression of PDE3A was probably not
the cause of the hypertension, but rather the result of an
increase in blood pressure with age [64]. Slightly different
rearrangements in this segment were found later in other
families, apart from the Turkish one [65]. Finally, in this
inverted sequence, a non-protein coding exon was found
Figure 5 Right hand in a non adult individual with
heterozygous mutation in PTHLH. Severe shortening of IV and V
metacarpals is clearly observed (courtesy of Dr. Cécile Teinturier-
Thomas, personal collection; Dr. Caroline Silve, molecular diagnosis,
unpublished case).
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arrangement could be the cause for this lack of expression.
This transcript was predicted to be an miRNA expressed
in primary fibroblasts [65]. The fibroblasts of affected fam-
ily members showed faster cell growth, but the function of
this miRNA remains to be clarified [65].
More severe cases caused by deletions in the 12p11.21-
12p.12.2 region were reported by Lu et al. [74] and Nagai
et al. [68]. One patient, with a deletion spanning 71 anno-
tated genes (PDE3A→BICD1), had moderate mental re-
tardation, short stature, borderline high blood pressure
(120/80 mmHg) and characteristic brachydactyly [74]. An-
other patient presented a more severe phenotype, mild
mental retardation, short stature, high blood pressure,
brachydactyly and cone-shaped epiphyses of the hands,
hypoplastic hair and skin, oligodontia, a small thoracic
cage and a hypoplastic pelvis [68]. The difference in the
severity between the patients might be attributable to the
extent of the deletion [74].
BDE with short stature, PTHLH type (OMIM#613382)
Maass et al. were the first to implicate the parathyroid
hormone-like hormone gene (PTHLH), localized to
12p11.22, in BDE, after the identification of a transloca-
tion, t(8;12) (q13;p11.2) in a family with autosomal-
dominant BDE and other malformations, including short
extremities, dysmorphic facies, macrocephaly, prominent
forehead and a depressed nasal root [76]. Despite the
PTHLH gene not being disrupted by the translocation, it
produced a downregulation of the gene and conse-
quently of its downstream targets, ADAMTS-7 and
ADAMTS-12 [76]. These genes are highly expressed in
chondrogenically differentiated fibroblasts, so they seem
to play an important role in chondrogenesis [77,78]. In a
more recent publication, Maass et al. proposed that the
downregulation of PTHLH, and its targets, was due to
the disruption of the interaction with a regulatory elem-
ent localized 24.43 Mb downstream of PTHLH, CISTR-
ACT [79]. This element is a cis-regulatory element of
PTHLH and also a trans-regulatory element of SOX9
(17q) [76,80], which is another essential gene in chon-
drogenesis whose haploinsufficiency causes skeletal
malformations [81]. This regulation occurs by an
lncRNA (DA125942), derived from the CISTR-ACT
locus, that coordinates the expression of SOX9 and
PTHLH generating a loop in the chromatin [79,80]. The
translocations t(8;12) (q13;p11.2) and t(4;12) (q13.2-
13.3;p11.2), later identified in another family, prevent
the formation of such a loop and result in overe-
xpression of the lncRNA and misexpression of PTHLH
and SOX9 [79,80].
In an independent study, a deletion and three point mu-
tations in the coding sequence of PTHLH were found to
be responsible for BDE with short stature [82]. Further, inan isolated case of symmetrical enchondromatosis caused
by a de novo duplication of 12p11.23 to 12p11.22 includ-
ing PTHLH, the patient showed BDE with cone-shaped
phalangeal epiphyses [83].
As in the previous group, the pattern of brachydactyly
varies considerably. Several authors have reported short-
ening of metacarpals III, IV and V in most cases, while
proximal, middle and distal phalange involvement was
variable and shortening and cone-shaped epiphyses on
middle and distal phalanges II and V were frequently
mentioned (Figure 5) [76,82,83]. In two cases (one pa-
tient with a deletion involving another 6 genes and the
second a carrier of a small duplication), metacarpals I
and II were also shortened [82,83], and in the case of
translocation t(8;12) mentioned above, shortening of
metacarpals I , III, IV and V was observed (Maass et al.;
IV:2 patient) [76].
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tients (Additional file 1: Table S6): most but not all had
short stature [76,82], tooth problems were reported by
Klopocki et al. in two out of five families [82], and those
affected with translocation t(8;12) had dysmorphic facies
with macrocephaly [76]. Neither hypertension nor men-
tal retardation was mentioned, but learning difficulties
were reported in one family [82].
AHO-like
Brachydactyly mental retardation syndrome (BDMR,
OMIM#600430) Brachydactyly mental retardation syn-
drome (BDMR), also referred to as Albright hereditary
osteodystrophy-like syndrome, is a rare pathology char-
acterized by variable features: short stature, obesity,
developmental delay, behavioural disorders, autism sp-
ectrum disorder and craniofacial and skeletal abnormal-
ities, like BDE (see Figure one at Fernandez-Rebollo
et al. [84]). Major malformations have also been repor-
ted, including cardiac, tracheal, gastrointestinal, genitouri-
nary, CNS and skeletal abnormalities (Additional file 1:
Table S7) [85,86].
This syndrome is caused by deletions in 2q37. Re-
cently, the minimum critical region responsible for this
syndrome has been mapped to the 200 kb which involve
the histone deacetylase 4 gene (HDAC4), localized
exactly to 2q37.3 [87]. In addition, point mutations in
HDAC4 have been found in two patients with BDMR
[88]. On the other hand, a patient with a deletion in
2q37.3, but not including HDAC4, exhibited a similar
phenotype but without BDE, cardiac or other major
malformations [88]. Given this, it was proposed that
HDAC4 haploinsufficiency could be causative of BDE in
this syndrome [88]. A recent report, of a family case
with a microdeletion involving HDAC4 and other two
genes, puts this statement in doubt, because none of the
three affected patients showed BDE [87]. So far, we
know that BDE is a variable feature and only reported in
about a half of patients with 2q37 microdeletions [87].
Histone deacetylase 4 is involved in bone, muscle,
neurological and cardiac development [89]. Felder et al.
demonstrated that FARP2, HDLBP and PASK genes were
downregulated in a patient with a 2q37.3 terminal dele-
tion compared to levels in his healthy family members
and controls [90]. These are good candidate genes be-
cause they are involved in neuronal and/or skeletal de-
velopment [90], but point mutations in these genes
which cause BDMR or other similar syndrome have not
yet been reported in the bibliography, except for the case
of a patient with autism associated with a de novo
MECP2 duplication who also had a second de novo du-
plication of 2q37.3 material involving PASK and HDLBP.
However, this patient did not have an AHO-like pheno-
type [91].BDE is only penetrant in 50-60% of cases and the pattern
profile is variable [88,92]. Frequently, metacarpals III and
IV and metatarsal IV are shortened, but other metacarpals
(II-V) have also been found to be affected, generally
sparing metacarpal/metatarsal I [86,88,90,93-98]. Further,
individuals with similar deletions or family members with
the same deletion may present different phenotypes; this
could be a result of incomplete penetrance of the
haploinsufficiency genes, epigenetics or regulation by other
genes [92].
It is worth mentioning that there is a very similar
syndrome, but without BDE, known as Smith-Magenis
syndrome (SMS; OMIM#182290) which is caused by dele-
tions in 17p11.2 or mutations in the RAI1 gene [88]. In
addition, RAI1 expression is reduced in BDMR cases [88].
Hence, when individuals are suspected of having the
BDMR phenotype, but no 2q37 deletions or HDAC4 mu-
tations are detected, deletions at 17p11.2 and the RAI1
gene should be analysed.
Acrodysostosis without multihormonal resistance
(ACRDYS2, OMIM:#614613) In acrodysostosis with-
out hormonal resistance, the affected gene is the
phosphodiesterase 4D, cAMP-specific (PDE4D) gene,
localized to 5q11.2 [44,46,49,99]. Clinical features
(Additional file 1: Table S4) are similar to ACRDYS1
apart from PTH resistance not generally being present
[44,99], though an exception was reported by Michot
et al. [46]. Other features it has been suggested may dif-
fer in the two types are: (i) facial dysostosis, which is
more evident in ACRDYS2 than in ACRDYS1; and (ii)
intellectual disability, which is common in ACRDYS2,
while ACRDYS1 has only been associated with some be-
havioural disorders and/or learning difficulties [44,46].
On the other hand, in the study of Lee et al. all patients
(three with PDE4D and two with PRKAR1A mutations)
had midface hypoplasia and there were no differences in
developmental disability according to the gene affected
(among those with PDE4D mutations, one was not af-
fected, a second was mildly affected and a third was sig-
nificantly affected; whereas both patients with PRKAR1A
mutations had mild developmental disabilities) [49].
Lynch et al. described eight patients; all of them had
some degree of learning difficulties, developmental delay
and intellectual disability [99]. These authors suggested
that in patients with acrodysostosis associated with
normal stature (only 5/15 presented short stature
[46,49,99]), progressive obesity (frequently developing
after 6 years of age), and mild intellectual disability but
no PTH resistance, PDE4D rather than PRKAR1A muta-
tions should be suspected. BDE, stenosis of the lumbar
spine, nasal hypoplasia, a flat nasal bridge and short stat-
ure are features shared by both subtypes of acrodysostosis
(see Figure three Pat. 15, 16 at Linglart et al. [44]). In
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with defects in either gene [44,49,99].
Thus, it is difficult to distinguish acrodysostosis cases
with PDE4D mutations from those with PRKAR1A mu-
tations on the basis of clinical observation only [49].
Therefore, biochemical studies of calcium and phos-
phorus metabolism are essential.
Tricho-rhino-phalangeal syndrome (TRPS) This
syndrome is classified into three types: TRPS I
(OMIM#190350), TRPS II (OMIM#150230) and TRPS III
(OMIM#190351). Mutations in the trichorhinophalangeal
syndrome I gene (TRPS1), localized to 8q23.3, have been
found in 88% of cases of TRSP I and TRSP III [100].
Lüdecke et al. described TRPS III as an extreme of the
clinical spectrum of TRSP I [100]. On the other hand,
TRPS II is a contiguous gene syndrome involving TRPS1
and EXT1 genes; patients develop cartilaginous exostoses
in addition to the features seen in TRPS I and III [100,101].
The striking features shared by the three types are
sparse, slowly growing scalp hair, laterally sparse eye-
brows, a bulbous tip of the nose (pear-shaped nose),
long flat philtrum, thin upper vermillion border and
protruding ears (see Figure three Momeni et al. [102])
(Additional file 1: Table S8) [100]. In radiography, the
main findings are: short stature, BDE, mild metaphyseal
convexity during the first year of life and premature fu-
sion of the growth plates of the tubular bonds [100].
Additionally, hip malformations (coxa plana, coxa
magna or coxa vara) have been reported in more than
70% of cases and degenerative arthrosis appears in older
individuals [100]. Patients show a retarded skeletal ageFigure 6 Hands of a patient with tricho-rhino-phalangeal syndrome I
metacarpals III and V are shortened on the left hand and IV and V on the r
epiphyses are shown with the typical outcarving and deformation (arrows)until puberty, and then an accelerated skeletal age,
while the mean length at birth is normal [100]. That is,
the growth retardation is a progressive process that can
be appreciated in metacarpophalangeal pattern profile
(MCPP) analysis comparing children and adults, and
comparisons of their relative height [100]. Growth hor-
mone deficiency has been reported in some cases
[103-105]. Intellectual disability has also been reported
in the three types, but most commonly in TRPS II
[100,101,106,107].
Regarding brachydactyly, shortening of the metacar-
pals has been reported in about half of patients and
cone-shaped epiphyses of middle phalanges, type 12/
12A (only appreciable after infancy in early childhood,
before epiphyses fuse), in almost all patients, in most
cases in mesophalanges II and III. Outcarving and de-
formation of the cones is another striking feature and
this is more easily appreciated after epiphysis fusion
(Figure 6) [108,109]. In addition, ivory cones were
reported by Giedion (again, a feature that is only appre-
ciable after infancy in early childhood, before epiphyses
fuse). Hypoplasia of the thumb, as well as shortening of
metacarpals II-V and of middle phalanges II and V is
frequently seen, although shortening of all middle pha-
langes has been also reported [101,106,108,110], as have
small feet and a short hallux [110]. Poznanski et al.
conducted MCPP analysis comparing PHP and PPHP
with TRPS and found no similarity between pattern pro-
files in the two syndromes [20]. These data were pub-
lished before the association of the syndrome with the
TRPS1 gene. More recently, Lüdecke et al. used MCPP
analysis to compare various groups of TRPS patients;(OMIM#190350). The patient presents asymmetrical brachydactyly;
ight. Further, middle phalanges are shortened and cone-shaped
(courtesy of Dr. Sharona Azriel, unpublished case).
Figure 7 Hand (A) and radius (B) of a patient with Turner syndrome. It can be observed the ulnar and palmar slant of the radial articular
surfaces, with a triangular appearance of the distal radial epiphysis and slight shortening of the IV metacarpal; the radius is short and bowed.
Figure 8 Proposed clinical algorithm to suggest the most probable genetic diagnosis. Features in brackets are not always present in the
syndromes. BDE Brachydactyly type E, PHP-Ia Pseudohypoparathyroidism type Ia, MLPA Multiplex ligation-dependent probe amplification, MS-MLPA
Methylation specific-MLPA.
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the brachydactyly was more marked in adults than in
children. On the other hand, patients with missense
mutations (TRPS III) had more severe brachydactyly
than the patients with the nonsense ones (TRPS I).
Given this, they classified the brachydactyly pattern
with respect to the mean profiles for TRSP I and TRSP
III, but these mean values were only intended for classi-
fication not to be used as a tool for diagnosis [100].
Additionally, patients with missense mutations were
shorter than the nonsense carriers, but patients with
gene contiguous syndrome (TRPS II) were the smallest
[100]. Finally, the brachydactyly pattern is variable, as
reflected in a lack of correlation between MCPPs in pa-
tients with the same recurrent mutation as well as the
presence of asymmetric brachydactyly in some patients
[100].
The severity of the TRPS phenotype might also depend
on the size of the deletion in 8q and whether there is mo-
saicism for the deletion, which has been reported in four
patients, two with TRPS I and two with TRPS II [101].
Turner syndrome (TS) Turner syndrome is a chromo-
somal disorder with a complete or partial monosomy of
X chromosome. The genetic background is variable, the
most frequent karyotypes are: 45,X (~50%), karyotypes
with an isochromosome of X (i(Xq) or i(Xp)), the mosaic
45,X/46XX (%30), and karyotypes containing an entire
or parts of Y chromosome [111,112].
The main features are short stature (90-100%), gonadal
dysgenesis, pubertal delay, primary amenorrhea (85%), es-
trogens insufficiency, cardiac anomalies and/or other con-
genital malformations like brachydactyly E (see Figure one
at Bondy [113]) [111,112,114-116]. Other frequent features
are: lymphedema, congenital malformations of the urinary
system (30-40%), abnormalities of the external ocular ap-
pendages, (epicanthal folds, ptosis, hypertelorism, upward
slanting palpebral fissures), strabismus and hypermetropia
(25–35%), hearing problems and ear malformations, dys-
morphic craniofacial features, abnormalities in tooth de-
velopment and morphology (early eruption), melanocytic
nevi, normal GH secretory pattern, altered liver enzymes¸
decreased bone mineral density, etc. [111,112,114-117]
(Additional file 1: Table S9).
Regarding brachydactyly E, the more typical brachy-
dactyly of Turner syndrome is the shortened of the IV
metacarpals, but it is variable [20,114,118]. Poznanski
compared the brachydactyly associated with PPHP-PHP
versus TS and observed that the shortening of the bones
are less severe in TS than in PPHP-PHP; shortening of
I distal (D1) phalanx’s is less frequent in TS (5% in con-
trast to the 75% of PPHP-PHP), so if a patient presents
short fourth metacarpals and a normal D1, it is more
probable that have Turner syndrome than PHP-PPHP.Finally, he mentions drum stick phalanges and thin
bones in TS (Figure 7) [20].
Although TS is quite well known entity, there is often
a delay in the diagnosis as over 20% of patients are diag-
nosed after 12 yr [115,119]. As other syndromes men-
tioned in this review, it is essential to be diagnosed
during infancy for proper early treatment to avoid com-
plications linked to TS. In fact there are some publica-
tions explaining the clinical guidelines to be followed to
optimize care for young woman and adults with TS
[111,112,114-117].Concluding remarks
The BDE pattern profile can vary considerably within a
syndrome, even between unrelated patients with identi-
cal mutations and among affected family members. In
addition, brachydactyly is sometimes not appreciable
until 6 years of age, because it is a progressive feature
and tends to become more evident during early puberty.
With the aim of helping to identify the most prob-
able genetic diagnosis to inform the clinical manage-
ment of the aforementioned syndromes with BDE, we
have established a diagnostic algorithm including spe-
cific differential features (Figure 8). In a multidisciplin-
ary approach for patients with BDE, there are some
very subtle but helpful clues that allow us to distin-
guish between some of the syndromes. (i) BDE ob-
served in individuals with acrodysostosis can be
differentiated fairly clearly because of its severity: all
the bones in the hand are affected and are charac-
teristically stocky in appearance [44,45,48]. (ii) TRPS
can also be easily recognised because the MCPP is sig-
nificantly different and there are also other characteris-
tic clinical features: sparse, slowly growing scalp hair
and a bulb-shaped nose are very suggestive of this
syndrome [20].
Poznanski et al. also carried out MCPP analysis com-
paring isolated BDE and PHP/PPHP, but at the time
these two syndromes had not been genetically well dif-
ferentiated and hence the conclusions may not be reli-
able [20]. Indeed, patients with different pathologies
could be confused if attention were to be focused on
radiographic findings alone; hence, biochemical analyses
should be included.
The other syndromes discussed have not yet been
compared by MCPP analysis, but it seems that the pat-
tern of brachydactyly does not differ appreciably be-
tween them. In such cases, when the BDE pattern is
not sufficiently informative, there are other features
which can help in the differentiation of each syndrome
(Additional file 1: Table S1). These features are listed
in the supplementary material (Additional file 1: Table
S2–S9).
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Additional file 1: Table S1. Summary of description of each syndrome.
ACRDYS: acrodysostosis; BDE: brachydactyly type E; BDMR: Brachydactyly
mental retardation syndrome; PHP: pseudohypoparathyrodism; TRPS:
Tricho-rhino-phalangeal syndrome. Table S2. Summary of the phenotype
associated with isolated BDE HOXD13 type [9-12]. Table S3. Summary of
the phenotype associated with PHP-Ia [27,29]. Table S4. Summary of the
phenotype of acrodysostosis [46,52,99]. Table S5. Summary of the
phenotype associated with Bilginturan BD or hypertension with
brachydactyly syndrome [54-66]. Table S6. Summary of the phenotype
associated with BDE with short stature, PTHLH type [76,82]. Table S7.
Summary of the phenotype associated with Brachydactyly mental
retardation syndrome [86,88,90,92]. Table S8. Summary of the phenotype
associated with TRPS [100,108]. Table S9. Summary of the phenotype
associated with Turner syndrome [111,112,114-117].
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